<DOC>
	<DOCNO>NCT01255709</DOCNO>
	<brief_summary>This study examine pharmacokinetic profile Armstrong 's proposed Epinephrine Inhalation Aerosol USP , HFA134a propel Metered Dose Inhaler ( MDI ) ( E004 ) , use stable isotope deuterium-labeled epinephrine ( epinephrine-d3 ) differentiate administer drug endogenous epinephrine , healthy male female adult volunteer .</brief_summary>
	<brief_title>Epinephrine Inhalation Aerosol USP , CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS</brief_title>
	<detailed_description>The current study design complement expand previous PK study , API-E004-CL-B API-E004-CL-B2 , emphasis lower E004 dose strength ( 90 100 mcg per inhalation ) , thorough evaluation E004 PK profile . Safety E004 also evaluate , augment dose condition .</detailed_description>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Generally healthy screening ; Body weight ≥ 50 kg men ≥ 45 kg woman ; Sitting blood pressure ≤ 135/90 mmHg ; Demonstrating negative hIV , HBsAG DCVAb screen test ; Women childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; Properly consent Other criterion apply A smoking history ≥10 packyears , smoke within 6 month prior Screening ; Upper respiratory tract infection within 2 wk , low respiratory tract infection within 4 wk , prior Screening ; Any current recent respiratory condition might significantly affect pharmacodynamic response study drug ; Known intolerance hypersensitivity study MDI ingredient ; Having investigational drug/device study , donate blood , last 30 day prior Screening ; Other criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>shortness breath</keyword>
	<keyword>wheeze</keyword>
</DOC>